ライフサイエンスコーパス: parthenolide

1 l alcohol, lanolin, tixocortol pivalate, and parthenolide.

2 in the presence of the NF-kappaB inhibitor, parthenolide.

3 s effectively blocked by NF-kappaB inhibitor parthenolide.

4 ancer cells treated with the cytotoxic agent parthenolide.

5 e NF-kappaB inhibition was assessed by using parthenolide.

6 t on NF-kappaB, as indicated by studies with parthenolide.

7 ich was inhibited by the NF-kappaB inhibitor parthenolide.

8 xel or nocodazole compromised the effects of parthenolide.

9 gets of the antiinflammatory natural product parthenolide.

10 Three groups of rats received parthenolide (0.25, 0.5, or 1 mg/kg) 15 min before endot

11 min before endotoxin; another group received parthenolide (1 mg/kg) 3 h after endotoxin.

12 A group of rats received parthenolide (1 mg/kg) intraperitoneally.

13 We demonstrate that the parthenolide, 2-deoxyglucose, temsirolimus (termed PDT)

14 tion, and iNOS expression were attenuated by parthenolide (3mg/kg), the active constituent of feverfe

15 We also show that parthenolide, a NF-kappaB inhibitor, sensitizes breast c

16 Parthenolide, a potent and specific inhibitor of NFkappa

17 Here, we show that parthenolide, a sesquiterpene lactone, selectively exhib

18 phenol found in the plant Curcuma longa, and parthenolide, a sesquiterpene lactone, suppress both lig

19 ned to investigate the biological effects of parthenolide, a specific inhibitor of NF-kappaB activati

20 eatment of C. pneumoniae-infected HUVEC with parthenolide, a specific inhibitor of NF-kappaB activati

21 nyl containing compounds ethacrynic acid and parthenolide activated Nrf2 in normal peripheral blood m

22 In this report, we show that parthenolide activates c-Jun N-terminal kinase (JNK), wh

23 In PC3 but not PrEC cells, parthenolide activates NADPH oxidase, leading to a decre

24 from the mitochondria in cells treated with parthenolide alone.

25 Treatment with parthenolide also abolished formation of nitrotyrosine a

26 Treatment with parthenolide also abolished nitrotyrosine formation, PAR

27 t on the response to LPS, LY294002 (LY2) and parthenolide (an IkappaB kinase inhibitor) were both pot

28 hibitor), wortmannin (a PI3K inhibitor), and parthenolide (an IkappaB kinase inhibitor), inhibited pa

29 Parthenolide, an active ingredient of herbal remedies su

30 itumor activity of the sesquiterpene lactone parthenolide, an active ingredient of medicinal plants,

31 As a starting point, we used parthenolide, an agent shown to target critical mechanis

32 ies, we used oligonucleotide microarrays and parthenolide, an NF-kappa B-specific inhibitor, to ident

33 The IKK inhibitors parthenolide and aspirin blocked the activities of infec

34 In vitro assays of the effect of parthenolide and Bay 11-7082 on the ATPase activity of N

35 Although parthenolide and BMS-345541 had no inhibitory effects on

36 The selective IKK inhibitors parthenolide and BMS-345541 prevented ovariectomy-induce

37 he therapeutic anti-inflammatory activity of parthenolide and identify vinyl sulfones as a new class

38 s and strongly suggest that a combination of parthenolide and tamoxifen may offer a novel therapeutic

39 1-7085, caffeic acid phenethyl ester (CAPE), parthenolide, and curcumin; protein kinase (PK)C inhibit

40 Eucalyptol, limonene, linalool, thymol, parthenolide, andrographolide, 18beta-glycyrrhetinic aci

41 LY2 but not parthenolide blocked the LPS-induced stabilization of FP

42 Parthenolide, but not wortmanin or the MAPK inhibitor PD

43 nstrate for the first time that curcumin and parthenolide can directly inhibit Nod2-mediated signalin

44 Parthenolide causes oxidative stress in PC3 cells but no

45 short total synthesis of the novel unnatural parthenolide diastereomer (+/-)-4,5-dia-parthenolide was

46 studies identified an analog, dimethylamino-parthenolide (DMAPT), which induces rapid death of prima

47 and the administration of the HDAC inhibitor parthenolide during obstructive cholestasis in vivo prom

48 ells (EC50 = 0.57-2.90 muM) when compared to parthenolide (EC50 = 6.0) and showed potent antileukemic

49 We previously showed that parthenolide enhances ROS production in prostate cancer

50 We conclude that parthenolide exerts beneficial effects during endotoxic

51 rmacological inhibition of detyrosination by parthenolide fully mimicked this axon growth promotion i

52 Importantly, when combined with radiation, parthenolide further increases ROS levels in PC3 cells w

53 or a small-molecule inhibitor of NF-kappaB (parthenolide; IC(50)=500 nM in tamoxifen-resistant cells

54 In vivo pretreatment and post-treatment with parthenolide improved the hemodynamic profile and reduce

55 In vivo treatment with parthenolide improved the hemodynamic profile and surviv

56 This study examines the effect of parthenolide in endotoxic shock in rodents.

57 DNA binding of NF-kappaB was inhibited by parthenolide in the lung, whereas degradation of IkappaB

58 gly, either local or systemic application of parthenolide in wild-type mice dose-dependently accelera

59 In contrast, parthenolide increases oxidation of KEAP1 in normal pros

60 In vivo, parthenolide increases radiosensitivity of mouse xenogra

61 Mechanistically, parthenolide increases the level of cellular ROS and cau

62 Parthenolide induced phosphorylation of Bid and increase

63 he JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis.

64 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a do

65 Parthenolide inhibited NF-kappaB activation in response

66 hat the herbal NF-kappaB inhibitory compound parthenolide inhibits the activity of multiple inflammas

67 Parthenolide is a sesquiterpene lactone used in folk med

68 c methods, we determined that treatment with parthenolide leads to induction of compensatory mechanis

69 of cells with a specific NFkappaB inhibitor, parthenolide, led to loss of NFkappaB activity and down-

70 he IKK inhibitors celastrol, BMS-345541, and parthenolide on bone cell function in vitro and ovariect

71 P1 in controlling the differential effect of parthenolide on tumor and normal cell radiosensitivity.

72 rmacological inhibition of detyrosination by parthenolide or cnicin mimicked this axon growth promoti

73 nce, the IKK inhibitors acetylsalicylate and parthenolide prevented FA-induced reductions in insulin-

74 iously shown that the plant-derived compound parthenolide (PTL) can impair the survival and leukemoge

75 trated that the naturally occurring compound parthenolide (PTL) can induce death of human LSCs in vit

76 Parthenolide (PTL) has been shown to cause apoptosis of

77 his premise, we identified compounds such as parthenolide (PTL) or piperlongumine that induce almost

78 The present studies demonstrate that parthenolide (PTL), a naturally occurring small molecule

79 s have shown that the sesquiterpene lactone, parthenolide (PTL), ablates bulk, progenitor, and stem A

80 emsirolimus as agents that can be added to a parthenolide regimen as a means to inhibit such compensa

81 with inhibition of NF-kappaB by gliotoxin or parthenolide resulting in the abrogation of hypoxic surv

82 Parthenolide reversed resistance of breast cancer cells

83 downstream redox target that contributes to parthenolide's radiosensitization effect in prostate can

84 Together, the results show that parthenolide selectively activates NADPH oxidase and med

85 riments, pretreatment or post-treatment with parthenolide significantly improved survival in mice cha

86 Parthenolide through JNK increased the TRAIL-mediated de

87 ells treated with a combination of TRAIL and parthenolide underwent massive typical apoptosis and aty

88 ural parthenolide diastereomer (+/-)-4,5-dia-parthenolide was accomplished in 13 steps and an overall

89 These beneficial effects of parthenolide were associated with reduction of NF-kappaB

90 results identify a new antitumor activity of parthenolide, which can be exploited to reverse resistan